The FDA's requirement of a new late-stage clinical study caused the biotech stock to plunge.
News & Analysis: CTI BioPharma
Read on to see which of these companies drew the ire of Donald Trump.
Shares tumble in response to disappointing clinical news. Here's what investors need to know.
The blood-cancer-focused biotech isn't out of the woods yet, but it looks like it will finally be allowed to continue an important clinical trial.
Another day, another stock offering for CTI BioPharma .
A shrinking cash balance and steady operating losses could spell trouble for these biotech stocks in 2016.
Pricing details on a recently announced capital raise have investors selling off shares.
With ongoing annual loss streaks of eight, 18, and 23 years, respectively, these companies might understandably seem hopeless.
With a heavy debt load, Incyte can't afford competition for Jakafi.
Shares of CTI Biopharma are up big today. Is the news meaningful, or just market noise?